Harmony Biosciences reports ~$868M FY2025 WAKIX revenue; guides $1.0-1.04B in 2026

Harmony Biosciences Holdings, Inc.

2025-FY EPS reported $2.71 revenue$868,453,000

Preliminary Q4 2025 WAKIX net revenue ~$243M; FY2025 ~$868M, up ~21% YoY.
2026 WAKIX net revenue guidance of $1.0-1.04B, on track for blockbuster status.
Pitolisant GR NDA submission expected 2Q 2026; PDUFA 1Q 2027; aims to extend franchise into 2040s.
Five ongoing Phase 3 reg. trials in CNS; topline data for pitolisant HD and EPX-100 in 2027.
ZYN002 program in Fragile X discontinued; 22q deletion syndrome indication no longer pursued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.